Skip Navigation LinksHome > December 22, 2000 - Volume 14 - Issue 18 > Rifabutin but not clarithromycin prevents cryptosporidiosis...
Clinical Science

Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection

Fichtenbaum, Carl J.a; Zackin, Robertb; Feinberg, Juditha; Benson, Constancec; Griffiths, Jeffrey K.d; the AIDS Clinical Trials Group New Works Concept Sheet Team 064

Collapse Box


Background: Macrolides have been reported to be effective for the prevention of cryptosporidiosis in persons with HIV infection.

Objective: To evaluate the efficacy of clarithromycin and rifabutin for the prevention of cryptosporidiosis in persons with advanced HIV infection.

Design: Cross-protocol analysis involving 2288 individuals with a history of a CD4 cell counts of ≤ 100 × 106 cell/l who were enrolled in two prospective clinical trials to prevent Mycobacterium avium complex (MAC) infection and cytomegalovirus (CMV) end-organ disease.

Interventions: Clarithromycin 500 mg twice daily, rifabutin 300–450 mg daily, the combination of the two or no MAC prophylaxis.

Main outcome measurement: Laboratory-confirmed cryptosporidiosis. Subjects were analyzed in an intent-to-treat and as-treated manner using time-to-event analyses (Cox proportional hazards models).

Results: The median length of follow up was 463 days. The median CD4 count at entry was 29 × 106 cell/l (range 0–182). There were 60 cases of cryptosporidiosis during the prospective observational period, with an event rate of 2.2 per 100 person-years. In the intent-to-treat [relative risk (RR) 0.50; 95% confidence interval (CI) 0.26–0.96;P = 0.04] and as-treated (RR 0.42; 95% CI 0.20–0.91;P = 0.03) analyses, rifabutin alone was significantly associated with a lower rate of cryptosporidiosis. Clarithromycin alone was not protective in similar analyses (P = 0.98 and 0.90, respectively).

Conclusions: In doses used to prevent MAC infection, rifabutin but not clarithromycin decreases the risk of developing cryptosporidiosis in persons with advanced HIV infection who are not receiving potent combination antiretroviral therapy.

© 2000 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.